In this context, estrogen receptor (ER) and progesterone receptor (PR) analysis in breast carcinomas were the first established biomarker assays with both prognostic and predictive power and they have been in use since the 1970s [7]. The gene discussed is ESR1; the disease is breast carcinoma.